Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

无容量 医学 临床终点 内科学 不利影响 实体瘤疗效评价标准 临床研究阶段 肿瘤科 临床试验 耐火材料(行星科学) 癌症 癌 胃肠病学 外科 免疫疗法 天体生物学 物理
作者
Toshihiro Kudo,Yasuo Hamamoto,Ken Kato,Takashi Ura,Takashi Kojima,Takahiro Tsushima,Shuichi Hironaka,Hiroki Hara,Taroh Satoh,Satoru Iwasa,Kei Muro,Hirofumi Yasui,Keiko Minashi,Kensei Yamaguchi,Atsushi Ohtsu,Yuichiro� Doki,Yuko Kitagawa
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (5): 631-639 被引量:374
标识
DOI:10.1016/s1470-2045(17)30181-x
摘要

Nivolumab is a human monoclonal IgG4 antibody that inhibits programmed cell death protein 1 (PD-1) expressed on activated T cells. We investigated the safety and activity of nivolumab in patients with treatment-refractory oesophageal cancer.We did an open-label, single-arm, multicentre phase 2 study. Eligible patients had advanced squamous-cell carcinoma, adenosquamous-cell carcinoma, or adenocarcinoma of the oesophagus refractory or intolerant to fluoropyrimidine-based, platinum-based, and taxane-based chemotherapy. Patients were treated with 3 mg/kg nivolumab given intravenously once every 2 weeks in 6-week cycles. The primary endpoint was centrally assessed objective response (the proportion of patients whose best response was complete or partial response), according to the Response Evaluation Criteria In Solid Tumors, version 1.1. Adverse events and treatment-related adverse events (defined as events for which a causal relation to nivolumab could not be ruled out) were monitored throughout the study. The safety analysis was done in patients who received at least one dose of nivolumab, and drug activity was assessed in patients who received at least one dose of nivolumab and had at least one central assessment of tumour response. This study is registered with clinicaltrials.jp, number ONO-4538-07/JapicCTI-No.142422. Follow-up of patients is ongoing.Between Feb 25 and Nov 14, 2014, 65 patients were enrolled, all with squamous-cell carcinoma. 64 patients were assessable for the primary endpoint as one patient was excluded due to having multiple primary cancers; all patients were assessable for safety. Median follow-up was 10·8 months (IQR 4·9-14·3). 11 (17%, 95% CI 10-28) of 64 patients had a centrally assessed objective response. Of the 65 patients assessed for adverse events, the most common grade 3 or 4 events were grade 4 dyspnoea and hyponatraemia (one [2%) patient each), grade 3 lung infection (five [8%] patients), grade 3 decreased appetite (two [3%] patients), grade 3 increased blood creatinine phosphokinase (two [3%] patients), and grade 3 dehydration (two [3%] patients). Serious adverse events that occurred during the study were lung infection (four [6%] patients), dehydration (two [3%]), interstitial lung disease (two [3%]), and hyponatraemia, dyspnoea, fatigue, abnormal hepatic function, diarrhoea, bile duct stenosis, gastroenteritis, pneumonia, oedema, and back pain (one [2%] patient each). There were no treatment-related deaths.Nivolumab showed promising activity with a manageable safety profile. This drug could offer a potential new treatment approach for patients with treatment-refractory advanced squamous-cell carcinoma.Ono Pharmaceutical, Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杜欣悦发布了新的文献求助10
刚刚
刚刚
多看点文献吧完成签到,获得积分10
刚刚
思源的应助被nxdr采纳,获得10
1秒前
冯梦梦完成签到,获得积分10
2秒前
之子之远完成签到,获得积分10
2秒前
传奇3的应助被MADAO采纳,获得30
4秒前
大白完成签到 ,获得积分10
4秒前
CITY111119发布了新的文献求助10
4秒前
4秒前
4秒前
zww113发布了新的文献求助10
4秒前
5秒前
冯梦梦发布了新的文献求助10
5秒前
童童完成签到,获得积分10
6秒前
6秒前
7ian完成签到 ,获得积分10
7秒前
欢喜夏天完成签到,获得积分10
7秒前
清辉影的应助被漫漫采纳,获得10
8秒前
9秒前
等风归发布了新的文献求助10
10秒前
11秒前
昏睡的绿海完成签到,获得积分10
11秒前
AKKK完成签到 ,获得积分10
11秒前
11秒前
逆流沙完成签到,获得积分10
12秒前
FashionBoy的应助被马亚斌采纳,获得10
12秒前
839788336完成签到,获得积分10
13秒前
归帆发布了新的文献求助10
13秒前
iNk的应助被ladywerwer采纳,获得10
14秒前
NUS完成签到,获得积分10
14秒前
gentle发布了新的文献求助10
14秒前
wspqbs关注了科研通微信公众号
15秒前
xiang完成签到,获得积分10
16秒前
erlangenbio完成签到,获得积分10
16秒前
16秒前
深情安青的应助被杜欣悦采纳,获得10
17秒前
18秒前
modoun完成签到,获得积分10
19秒前
iNk的应助被ladywerwer采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621